Responses over time with subcutaneous teclistamab. Responses in patients occurred early, deepened over time, and were durable. The median time to first response was 1.2 months (range, 0.2-4.9), time to best response was 2.9 months (range, 1.1-12.3), and time to CR or better was 4.0 months (range, 2.1-12.3). D/C, discontinued; PD, progressive disease.